Pharmaceutical Industry in
Monthey

Excellgene SA

Since 2004 · 11–20 empl.·5.0(1)

ExcellGene is a Swiss Biologics-CDMO (Contract Development and Manufacturing Organization) specialized in the development and manufacturing of proteins for the pharmaceutical industry. The company's core activity encompasses providing services for the development and manufacturing of biologics, including: cell line development (CHO and HEK cells), genome engineering, cGMP cell banking, process development, ensuring clonality of existing cell lines, and biosimilars. The company supports pharmaceutical companies in the development and manufacturing of proteins for drug development, offering a combination of scientific expertise and technological infrastructure.

IHMA Europe Sàrl

Since 2009 · 21–50 empl.·5.0(1)

The core activity of International Health Management Associates (IHMA) is to support pharmaceutical companies in the development of medicines, particularly in the area of antimicrobial therapies. IHMA offers a wide range of services, including: * Drug Discovery: Identification and development of new medicines * Clinical Development: Conducting clinical trials and tests * Regulatory Submissions: Supporting the approval of medicines by regulatory authorities * Commercialization: Supporting the market launch and marketing of medicines IHMA has its own laboratories and uses modern technologies to deliver high-quality tests and data. The company works closely with healthcare institutions and pharmaceutical companies to enable successful drug developments.

INFLAMALPS SA

Since 2012 · 11–20 empl.

The core activity of Inflamalps SA is the development of biopharmaceutical products, particularly the discovery and development of anti-inflammatory and anti-microbial molecules for the treatment of diseases, such as dry eye in ophthalmology.

Swiss Biotech Center SA

Since 2016 · 11–20 empl.

The core activity of Swiss Biotech Center is the development and manufacture of biopharmaceutical products, in particular biological medicines, as well as supporting start-ups and companies in the development and marketing of biopharmaceutical products. The company offers services such as research and development, clinical development, manufacturing and marketing of biopharmaceutical products and has an extensive network and expertise in the biotechnology industry.

Celluris AG

Since 2016 · 21–50 empl.

The core activity of Celluris is the development and research of personalized cancer treatments through CAR-T immunotherapy, specifically the modification of patient cells to recognize and combat tumors.

BioXpress Therapeutics SA

Since 2008 · 11–20 empl.

The core activity of BioXpress Therapeutics SA is the development and manufacturing of biosimilars, in particular monoclonal antibodies (mAb), as well as other biological medicines, including gene therapy and cell therapy candidates. The company focuses on developing high-quality, sustainably manufactured biosimilars that aim to improve access to life-saving treatments and reduce healthcare costs.

ImmunSkills SA

Since 2022 · 11–20 empl.

ImmunSkills SA develops allogenic cell‑based therapies for solid cancers, aiming to create a product using allogenic cells that can kill various cancer cells and modify the tumour microenvironment to reduce treatment resistance.

Stämm Vegh SA

Since 2023 · 1–10 empl.

Stämm Vegh SA develops solutions for biomanufacturing, bioengineering and bio‑AI to support biologics and cell therapy production and cell line development. Its offerings include a plug‑and‑play continuous bioreactor (the Bioprocessor) with a bubble‑free bioreactor, automated cell‑line engineering and clone‑selection platforms, and MoNA™ — a transomics platform for multi‑omic analysis and in‑silico cell simulation.

Orio Therapeutics SA

Since 2023 · 1–10 empl.

Orio Therapeutics' core activity is the development of protein-based therapeutics for regenerative medicine, particularly for the treatment of heart attacks. The company focuses on modifying therapeutic proteins to control their localization and delivery, thereby improving efficacy and reducing dosing.

ExcellGene Group SA

Since 2025 · 1–10 empl.

ExcellGene Group SA is a Swiss biologics development company focused on mammalian cell protein expression and bioprocess development. The company supports projects from discovery through development to manufacturing and offers platforms, cell lines, and process and analytical development services.

SILDERMA SARL

Since 2007 · 1–10 empl.

Caravella Biopharma SA

Since 2016 · 1–10 empl.